Research analysts covering XORTX Therapeutics.
Recent press releases and 8-K filings for XRTX.
XORTX Announces Pioneering Gout Research and Provides Corporate Update
XRTX
Board Change
New Projects/Investments
- XORTX announced pioneering research on genome-wide pathogenic pathways in gout, which supports its approach to treating gout and kidney diseases by inhibiting xanthine oxidase (XO). The company plans a clinical trial using its commercial formulation of oxypurinol to prepare for a New Drug Application (NDA) for gout therapy.
- The company clarified details of its US$1.1 million Registered Direct Offering, stating it issued 572,470 common shares and 1,177,530 pre-funded warrants for a total of 1,750,000 common shares and pre-funded warrants. D. Boral Capital LLC also received 87,500 agent warrants and a cash commission of USD$77,175.
- XORTX provided an update on the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited, with closing expected no later than January 13, 2026, pending ASX approval.
- Krysta Davies Foss was appointed as a director, while Bill Farley, Abigail Jenkins, and Patrick Treanor resigned, reducing the board to five members.
Jan 2, 2026, 7:37 PM
XORTX Therapeutics Highlights Research, Announces Board Changes, Clarifies Offering, and Updates on Acquisition
XRTX
Board Change
New Projects/Investments
- XORTX Therapeutics highlighted recent peer-reviewed research supporting the link between genetic factors, xanthine oxidase over-expression, and diseases like gout and kidney disease, reinforcing the company's strategy to treat these conditions by inhibiting XO and advancing a planned clinical trial for oxypurinol towards a New Drug Application (NDA).
- The company announced board changes, including the appointment of Krysta Davies Foss as a director and the resignations of three members, reducing the board to five members.
- XORTX clarified its October 29, 2025, Registered Direct Offering, confirming 1,177,530 pre-funded warrants were issued, and D. Boral Capital LLC received a cash commission of USD$77,175.
- An update was provided on the acquisition of the Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems, with closing anticipated by January 13, 2026, pending ASX approval.
Dec 31, 2025, 11:15 PM
XORTX Therapeutics Inc. Reports Q3 2025 Results, Announces Financing and Acquisition
XRTX
Earnings
M&A
New Projects/Investments
- XORTX Therapeutics Inc. reported a net loss of $649,469 for the three months ended September 30, 2025, compared to a net loss of $587,011 for the same period in 2024. For the nine months ended September 30, 2025, the net loss was $2,065,842, an improvement from $3,435,881 in the prior year period.
- The company's cash balance was $1,193,915 as of September 30, 2025, down from $2,473,649 at December 31, 2024. Cash used in operating activities for the nine months ended September 30, 2025, was $2,066,866.
- XORTX completed several financing activities, including an at-the-market offering in January 2025 and private placements in July and August 2025, raising aggregate gross proceeds of $1,153,047 for the nine months ended September 30, 2025. Subsequent to the quarter, the company closed a registered direct offering in October 2025, raising $1,102,500 in gross proceeds.
- In October 2025, XORTX entered a binding term sheet to acquire a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited for $3.0 million, payable in common shares. The company also received a European patent grant for "Xanthine Oxidase Inhibitor Formulations" in April 2025 and clarified the FDA NDA submission pathway for its XRx-026 program.
Nov 17, 2025, 9:17 PM
XORTX Therapeutics Inc. Closes US$1.1 Million Registered Direct Offering
XRTX
- XORTX Therapeutics Inc. closed a registered direct offering on October 29, 2025, generating US$1.1 million in gross proceeds.
- The offering involved the purchase and sale of 1,750,000 common shares (or pre-funded warrants in lieu thereof) at a price of US$0.63 per common share.
- The company issued 572,470 Common Shares and 1,117,530 Pre-Funded Warrants, with net proceeds intended for working capital and general corporate purposes.
Oct 31, 2025, 8:15 PM
XORTX Therapeutics Inc. Closes Registered Direct Offering
XRTX
- XORTX Therapeutics Inc. closed a registered direct offering on October 29, 2025, generating US$1,102,500.00 in gross proceeds.
- The offering included the purchase and sale of 1,750,000 common shares or pre-funded warrants at a price of US$0.63 per common share.
- The net proceeds from the offering are intended for working capital and general corporate purposes.
- D. Boral Capital LLC, the sole placement agent, will receive 87,500 agent warrants, exercisable at US$0.69 per common share.
Oct 29, 2025, 2:05 PM
XORTX Therapeutics Inc. Receives Nasdaq Minimum Bid Price Deficiency Notification
XRTX
Delisting/Listing Issues
- XORTX Therapeutics Inc. received a notification from Nasdaq stating non-compliance with the minimum bid price requirement.
- The company's common shares traded below US$1.00 for 30 consecutive business days, violating Nasdaq Rule 5550(a)(2).
- XORTX has a period of 180 calendar days from the notification date to regain compliance, which requires the bid price to close at or above US$1.00 for a minimum of 10 consecutive business days.
- This notification does not immediately impact the company's listing on the Nasdaq Capital Market or its compliance status with the TSX Venture Exchange.
Oct 21, 2025, 1:20 PM
XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
XRTX
- XORTX Therapeutics Inc. has announced the pricing of a registered direct offering.
- The offering involves the sale of 1,746,631 common shares (or common share equivalents) to an institutional investor at a purchase price of US$0.63 per common share.
- The company expects to receive gross proceeds of US$1.1 million from this offering.
- The net proceeds are intended for working capital and general corporate purposes.
- The closing of the offering is anticipated to occur on or about October 22, 2025.
Oct 21, 2025, 12:08 PM
XORTX Therapeutics Inc. announces 180-day extension to regain Nasdaq minimum bid price compliance
XRTX
Delisting/Listing Issues
- XORTX Therapeutics Inc. received a notice from Nasdaq on October 20, 2025, granting a 180-day extension to regain compliance with the US$1.00 per share minimum bid price requirement.
- The company's new deadline to meet this requirement is April 13, 2026.
- To achieve compliance, the closing bid price of the common shares must be at least $1 per share for a minimum of 10 consecutive business days.
- Failure to demonstrate compliance by April 13, 2026, could lead to delisting from Nasdaq, although the company would have the option to appeal this determination.
Oct 21, 2025, 12:44 AM
XORTX Therapeutics Inc. Releases Pro-forma Interim Balance Sheet for Q3 2025
XRTX
New Projects/Investments
- XORTX Therapeutics Inc. published its Pro-forma Interim Interim Balance Sheet as of September 30, 2025, and October 16, 2025.
- The company's Total Assets significantly increased from $2,811,078 on September 30, 2025, to $6,061,078 on October 16, 2025, primarily due to $3,250,000 in acquired assets.
- Total Shareholders' Equity rose from $1,973,670 to $5,073,670 between September 30, 2025, and October 16, 2025, largely driven by a $3,100,000 increase in reserves.
Oct 17, 2025, 11:19 AM
XORTX Therapeutics Inc. Announces Acquisition of Renal Anti-Fibrotic Therapeutic Program
XRTX
M&A
New Projects/Investments
- XORTX Therapeutics Inc. announced on October 17, 2025, the acquisition of a Renal Anti-Fibrotic Therapeutic Program from Vectus Biosystems Limited.
- The acquired program includes VB4-P5, a novel new chemical entity at the pre-IND stage of development, which has demonstrated potential to inhibit and possibly reverse kidney fibrosis.
- This program targets both rare and prevalent forms of kidney disease, addressing a substantial unmet medical need as there are no approved therapies specifically targeting or reversing kidney fibrosis.
- The consideration for the acquisition is USD $3.0 million, payable in common shares or common share equivalents of XORTX at a deemed issue price of USD $0.86 per Security.
- VB4-P5 benefits from robust global patent protection, covering composition-of-matter and method-of-use claims across more than 30 global jurisdictions.
Oct 17, 2025, 11:18 AM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more